Scalp metastasis from occult primary breast carcinoma: A case report and review of the literature☆,☆☆

N. Alizadeh, MD a, H. Mirpour, MD b, S.Z. Azimi, MD a,⁎

a Skin Research Center, Department of Dermatology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
b Department of Hematology and Oncology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Abstract

Background: Isolated distant cutaneous metastasis of breast carcinoma is uncommon. Furthermore, isolated metastasis of the scalp seems to be very rare in breast cancer.

Case presentation: A 44-year-old woman was referred to our dermatology department with concerns of a firm, painless, immobile, hardened, skin-colored mass fixed to the underlying tissues. The lesion measured 2 to 3 cm on the scalp frontalis without regional or distant lymphadenopathy. The patient had a history of benign right breast biopsy test results.

Immunohistochemistry test results were positive for cytokeratin (AE1/AE3), cytokeratin 7, chromogranin, estrogen receptor, and gross cystic disease fluid protein-15; group PR/HER2 were both weakly positive. Cytokeratin 20, thyroid-lung transcription factor, S100 protein, vimentin and thyroglobulin were all negative. Pathology test results showed adenocarcinoma that was consistent with breast primary.

Conclusion: Although cutaneous metastasis of the chest wall due to breast carcinoma is a common condition, scalp metastasis as the first sign of occult breast cancer is an extremely rare condition. We describe an isolated scalp metastasis as the initial presentation of breast cancer in a young woman in this report, which highlights that health care providers should be alert to the possibility that atypical soft tissue masses may represent a neoplasm. Further consideration of the scalp lesions among healthy looking patients is recommended.

© 2018 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Herein, we review the literature on cutaneous scalp metastasis from occult primary breast carcinoma. We illustrate the issue with the example of a 44-year-old female patient who presented with a frontal scalp cutaneous mass, but imaging modalities such as mammography and ultrasound found no primary breast cancer, and positron emission tomography revealed no particular metastases in her breast or other organs. Histopathology test results showed adenocarcinoma with neuroendocrine features and positive estrogen receptors. Although the primary cancer site was not determined, pathologists and oncologists suspected that it arose from indolent breast adenocarcinoma.

Isolated distant cutaneous metastasis of breast carcinoma is uncommon. Scalp involvement is very rare in breast cancer (Prabhu et al., 2009). Cutaneous metastasis usually presents with direct invasion or local infiltration, which indicates advanced disease (Prabhu et al., 2009; Shafiuddin et al., 2014). The expected survival rate at the time of diagnosis with cutaneous metastasis from breast cancer is estimated at <1 year. The survival benefit of chemotherapy in the management of patients with occult primary breast carcinoma is not definitive. Our patient responded well to the treatment without recurrence after 3 years of follow up.

Case history

A 44-year-old female patient presented to our practice with a painless left frontal scalp mass of 1-year duration. She had a history of a benign breast cyst with a right breast cystectomy secondary to fi broblastic changes 3 years ago, but was otherwise healthy with no history of weight loss.

The frontal scalp mass was skin-colored, nontender, hard, immobile, and measured 2.5 cm. (Fig. 1). There was no regional or distant lymphadenopathy. Clinically, the breast examination was unremarkable.
and graft of the scalp mass (Fig. 5). After a period of radiation therapy, cycles of docetaxel. Subsequently, the patient had a surgical removal of four cycles of adriamycin and cyclophosphamide, followed by four cycles of adriamycin and cyclophosphamide. She was initiated on systemic chemotherapy, consisting of good response to treatment without recurrence with 3 years of follow-up. Close observation rather than breast surgery was recommended for this patient.

**Discussion**

Isolated distant cutaneous metastasis of breast carcinoma is uncommon, and scalp involvement is very rare in breast cancer (Prabhu et al., 2009). Cutaneous metastases comprise 0.7% to 9% of all metastases and may be the first manifestation of internal malignancy or a sign of recurrence and poor prognosis (Prabhu et al., 2009). Scalp tumors account for 2% of all skin tumors and may originate from the epithelium, pilosebaceous unit, eccrine, and apocrine or present as metastases (Prabhu et al., 2009).

Lookingbill et al. (1990) conducted a systematic review of 7316 patients with cancer and found 367 cases (5.0%) with cutaneous involvement. Among these cases, cutaneous involvement was present in 92 at the time of presentation (1.3%); skin involvement was the first manifestation of cancer in 59 patients (0.8%); 22 cases had direct expansion of the tumor into the skin, with 20 and 17 with local and distal metastases, respectively. Chuang et al. (2007) found metastatic tumors in 12.8% of cases with malignant scalp lesions. Lung cancer was the most common primary tumor, followed by cancers of the colon (11.76%), liver (7.84%), and breast (7.84%). Of note, metastatic tumors of undetermined origin accounted for 29.41% of all metastatic scalp tumors.

Breast cancer is the most common malignant neoplasm in women. Approximately 6% of patients have de novo metastatic breast cancer. Occult breast cancer accounts for only 0.1% to 0.8% of cases and most commonly presents with axillary lymphadenopathy. Cutaneous metastases of breast carcinoma usually arise in the overlying skin or proximal to the primary tumor. There are different morphological types of cutaneous metastasis of breast carcinoma, including solitary to multiple erythematous infiltrating nodules or masses, carcinoma erysipeloides, carcinoma en cuirasse, carcinoma telangiectaticum, alopecia neoplastica, and zosteriform pattern (Rolz-Cruz and Kim, 2008; Santos-Juanes et al., 2007).

In 2011, Kuwayama et al. reported on a woman with a hard, alopecic mass on her scalp. Skin biopsy and histopathological assay test results revealed adenocarcinoma. Scalp metastases in breast cancer usually present in conjunction with other sites of disease and after detection of a primary tumor. Scalp metastases are rare and have been described as a sign of progression or widespread metastatic disease (Prabhu et al., 2009).

Blood test results showed elevated tumor markers, carcinoembryonic antigen (CEA) (37 ng/ml [normal up to 3.5 ng/ml]), elevated CA125 (34.7 U/ml [normal < 35 U/ml]), and normal CA19.9 (< 0.3 U/ml [normal < 37 U/ml]).

A punch biopsy was performed. Histology test results showed a deposition of somehow differentiated adenocarcinoma with neuroendocrine features (Fig. 2) Immunohistochemistry results (Table 1) showed a pattern that was more favorable of metastatic carcinoma of a primary breast neoplasm (Figs. 2-4).

The patient underwent several imaging tests (whole body bone scintigraphy, brain magnetic resonance imaging [MRI], abdominal U/S, breast and lymph nodes U/S, chest computed tomography with and without contrast, and breast MRI), and all imaging results were essentially normal. The detailed results are as follows:

- Whole body bone scintigraphy demonstrated abnormal increased uptake in the right femoral head without considerable abnormal uptake through the rest of skeleton.
- Brain MRI revealed plate-like, well-defined signal abnormality (low on T1, intermediate on T2W. FLAIR) in the subcutaneous adipose tissue of left superior frontal region with remarkable enhancement. The mass had no intracranial extension.
- Abdominal ultrasound was unaltered.
- Ultrasonography of the breast and lymph nodes showed normal echo without cystic or solid lesions and no pathologic lymph nodes.
- CT of the chest with and without contrast showed wedge-shaped consolidation in right middle lobe with air bronchospasm. Areas of ground glass opacity in right and left upper lobes. Findings were compatible with pneumonia and resolved with antibiotic therapy. No definite evidence of mediastinal lymphadenopathy or pleural effusion was observed.
- Breast MRI showed no obvious mass or abnormal enhancing area in either breast; however, reactive-appearing lymph nodes in the axillary regions were observed and presented generally benign findings.

We referred the patient to an oncologist for further evaluation and treatment. She was initiated on systemic chemotherapy, consisting of four cycles of Adriamycin and cyclophosphamide, followed by four cycles of docetaxel. Subsequently, the patient had a surgical removal and graft of the scalp mass (Fig. 5). After a period of radiation therapy, the patient continued on tamoxifen 20 mg/day. Our patient had a good response to treatment without recurrence with 3 years of follow-up. Close observation rather than breast surgery was recommended for this patient.

**Fig. 1.** Metastatic cutaneous mass over the frontal scalp of a 44-year-old female patient.
Shelke et al. (2012) reported on multiple cutaneous metastases from ductal carcinoma of the breast in a male patient. The researchers showed multiple nonulcerated, firm-to-hard papulonodular lesions on the chest, abdomen, extremities, and scalp. In our case, the female patient presented with a scalp tumor from indolent breast adenocarcinoma before revealing the breast imaging modalities. The diagnosis of cutaneous metastasis in the absence of a known primary requires a careful pathologic and radiologic workup to rule out other possible primary sites. Treatment and prognosis in each primary differ; thus, a definitive diagnosis is of the utmost importance.

Apocrine carcinomas characteristics from the scalp or elsewhere are similar to those of cutaneous metastases of breast adenocarcinoma (female breast can be thought of as a modified apocrine gland). From the pathology's point of view, the main differential diagnosis of a subcutaneous adenocarcinoma of unknown etiology is a primary skin adnexal (sweat gland) adenocarcinoma. Because a

### Table 1
Summary of immunohistochemical stain findings

| Antibody                                      | Result |
|-----------------------------------------------|--------|
| Cytokeratin (AE1/AE3)                         | +      |
| Cytokeratin 7                                 | +      |
| Chromogranin                                  | +      |
| Estrogen receptor                             | +      |
| Gross cystic disease fluid protein-15         | +      |
| GATA3                                         | +      |
| Mammaglobin                                   | +      |
| Progesterone receptor                         | +/-    |
| Her2neu                                       | +/-    |
| Cytokeratin 20                                | -      |
| Thyroid-lung transcription factor (TTF-1)     | -      |
| P63                                           | -      |
| Vimentin                                      | -      |
| Thyroglobulin                                 | -      |
| CK5/6                                         | -      |

**Fig. 2.** Histopathologic study of frontal mass biopsy, stained by hematoxylin and eosin and immunohistochemistry. (A) 1 and 2 low and high magnification respectively, hematoxylin and eosin, deposits of malignant epithelial neoplasm with minute foci of calcification and necrosis (adenocarcinoma with neuroendocrine feature); (B) 1 and 2 low and high magnification respectively, immunohistochemistry with cytokeratins strongly positive for the tumor cells; (C) 1 and 2 low and high magnification respectively, positivity for CK7 within the tumor cells.
single specific marker in the differentiation between breast carcinoma and skin adnexal tumors has not been identified thus far, a panel of immunohistochemical stains should always be performed. Also, in a skin adnexal adenocarcinoma, primary sites of malignant neoplasms other than breast carcinoma should always be excluded, such as lung, ovarian, and colon cancer, as well as melanoma and sarcoma (Alcaraz et al., 2012; Krathen et al., 2003; Lookingbill et al., 1990; Obaidat et al., 2007; Tlemcani et al., 2010).

An example is the case report of a 60-year-old woman who had primary scalp cutaneous apocrine carcinoma that was first misdiagnosed as cutaneous metastasis from breast adenocarcinoma (Kim et al., 2012). Another example is a case report of the axillary cutaneous apocrine carcinoma mimicking the metastatic lobular breast carcinoma. Immunohistochemistry demonstrated solid apocrine carcinoma of the skin (Zelger et al., 2008).

Taking into consideration the patient’s clinical history and tumor morphology, metastatic carcinomas usually can be distinguished from primary cutaneous cancers by typical histopathological patterns, such as the epidermal connection, intraepidermal, or intraadnexal (in situ component) tumor, or the presence of a benign counterpart in primary cutaneous cancers (Nibhoria et al., 2014). Immunohistochemical staining, particularly with cathepsin D, which is an aspartic protease and predominantly seen in breast carcinoma metastases, is of diagnostic value (Borkar and Pandit-Taskar, 2008; Manohar et al., 2012). P63 is a useful marker to distinguish between metastatic tumors and primary cutaneous adnexal tumors (Rollins-Raval et al., 2011).

Sihito et al. (2011), in a nationwide cohort study, found that tumors with early skin metastases expressed infrequently E-cadherin as a predictor of the preferential distant metastasis site. Additionally, pan-cytokeratins, epithelial membrane antigen, and carcinoembryonic antigen also stain positive in the majority cases, and reactivity of the metastatic tumor to androgen receptor is a key point toward the primary origin of breast carcinoma (Prabhu et al., 2009). Imaging that
uses positron emission/computed tomography scans is advised to stage breast cancer and revealed to be better than conventional imaging (Manohar et al., 2012; Borkar and Pandit-Taskar, 2008). Two known cases of breast carcinoma were reported with distant asymptomatic skin metastases (scalp and eyelid), which were incidentally detected with a positron emission tomography scan (Schwartz, 1995).

However, despite improvements in breast imaging, the frequency of detection of a primary tumor in that particular context has not substantially improved over time. Furthermore, immunohistochemical stains are not very sensitive, with a positive result for approximately half of the primary breast carcinomas for mammaglobin and approximately 30% for GCDFP-15. Estrogen receptor can also be expressed by primary sweat gland adenocarcinomas. The majority of breast carcinomas are positive for CK7 and negative for CK20. However, rare cases of CK7-negative breast carcinomas exist. GATA-3 has become popular in the breast cancer literature as a sensitive marker for breast carcinoma but lacks specificity and thus should always be used in conjunction with other markers (Bhargava et al., 2007; Cohen et al., 2009; Huo et al., 2013; Kaufman et al., 2003; Klein et al., 2005; Mentrikoski and Wick, 2015; Sellheyer and Krahl, 2010).

**Conclusion**

This report illustrates a very rare case of scalp metastasis as the first sign of occult breast cancer and shows that the diagnosis of a cutaneous mass in the absence of a known primary lesion requires a careful pathologic and radiologic workup to rule out other possible primary sites.

The close resemblance of immunohistochemistry in cutaneous adnexal carcinomas versus metastatic adenocarcinomas requires meticulous pathologic and radiologic analyses to establish a conclusive diagnosis.

**Acknowledgments**

The authors acknowledge Professor Gerard Bodeker and Dr. Alireza Mesbah for their contributions.
References

Alcaraz I, Cerroni L, Rütten A, Kutzner H, Requena L. Cutaneous metastases from inter-
malignancies: A clinicopathologic and immunohistochemical review. Am J
Dermatopathol 2012;34:347–93.

Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: An immunohisto-
logic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103–13.

Borkar S, Pandit-Taskar N, F-18 FDG uptake in cutaneous metastases from breast cancer. Clin Nucl Med 2008;33(7):485–9.

Chuang YH, Chiu CS, Lin CY, Kuo TT, Kuan YZ, Chen MJ, et al. Malignant cutaneous tu-
mors of the scalp: A study of demographic characteristics and histologic distribu-
tions of 398 Taiwanese patients. J Am Acad Dermatol 2007;56(3):448–52.

Cohen M, Cassarino DS, Shih HB, Abemayor E, St John M. Apocrine hidradenocarcinoma from cutaneous metastasis of breast carcinoma: A classi-
fication conundrum. Head Neck Pathol 2009;3(1):42e6.

Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, et al. Expression of
mammaglobin and gross cystic disease fluid protein-15 in breast carcino-
as. Hum Pathol 2013;44:1241–50.

Kaufman CK, Zhou P, Pasolli HA, Rendl M, Bolotin D, Lim KC, et al. GATA-3: An unexpected regulator of cell lineage determination in skin. Genes Dev 2003;17:2108–22.

Kim HK, Chung KJ, Park BY, Bae TH, Kim WS, Lee TJ. Primary apocrine carcinoma of
scalp: Report of primary scalp cutaneous apocrine carcinoma indistinguishable from cutaneous metastasis of breast carcinoma. J Plast Reconstr Aesthet Surg 2012;65(3):e67–70.

Klein W, Chan E, Seykora JT. Tumors of the epidermal appendages. In: Elder DE, editor.
Lever’s histopathology of the skin. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 867e926.

Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: A meta-analysis of data. South Med J 2003;96:164–7.

Kuwajama T, Sato T, Nakagawa T, Sugimoto H, Ichiba T, Kubota K, et al. A case of scalp
metastases from breast cancer successfully treated with letrozole. Gan To Kagaku
Ryoho 2011;38(12):2183–9.

Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of in-
ternal malignancy. A retrospective study of 7316 cancer patients. J Am Acad
Dermatol 1990;22:19–26.

Manohar K, Mittal BR, Bhattacharya A, Singh G. Asymptomatic distant subcutaneous metastases detected by F-FDG-PET/CT in a patient with breast carcinoma. World J Nucl Med 2012;11(1):24–5.

Mentrikoski MJ, Wick MR. Immunohistochemical distinction of primary sweat gland carcinoma and metastatic breast carcinoma: can it always be accomplished reli-
ably? Am J Clin Pathol 2015;143(3):430–6.

Nihihoria S, Tiwana KK, Kaur M, Kumar S. A clinicopathological and immunohisto-
chemical correlation in cutaneous metastases from internal malignancies: A five-year study. J Skin Cancer 2014;2014:793937.

Obidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms-part 2: An approach to
tumors of cutaneous sweat glands. J Clin Pathol 2007;60(2):145e59.

Prabhuj S, Pal SB, Handaturu S, Kuder MH, Vasanth V. Cutaneous metastases from carcino-
noma breast: The common and the rare. Indian J Dermatol Venereol Leprol 2009;
75(5):499–502.

Rollins-Raval M, Chivukula M, Tseng GC, Jukic D, Dabbs DJ. An immunohistochemical
panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature. Arch Pathol Lab Med 2011;135
(8):975–83.

Roltz-Cruz G, Kim CC. Tumor invasion of the skin. Dermatol Clin 2008;26:89–102.

Santos-Juanes J, Lopez-Escobar M, Palicio NV, Rivas BM, Galache C, Sanchez del Rio J,
et al. Zosteriform cutaneous metastasis from a breast carcinoma. Med Cutan Iber Lat Am 2007;35:89–93.

Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol 1995;33(2):161–82.

Sellhewer K, Krahl D. Expression pattern of GATA-3 in embryonic and fetal human skin
suggests a role in epidermal and follicular morphogenesis. J Cutan Pathol 2010;37
357–61.

Shafuddin M, Rohit RHR, Hubli P. Review literature of a case of multiple distant cutane-
ous metastasis from carcinoma breast. J Evol Med Dent Sci 2014;3(69):14835–9.

Shelke VN, Khandekar SL, Lodha ND, Raut WK. Multiple remote cutaneous metastases
from male breast carcinoma-cytodiagnosis of a case. J Cytol Histol 2012;3:148.

Sihot H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer bio-
logical subtypes and protein expression predict for the preferential distant metas-
tasis sites: A nationwide cohort study. Breast Cancer Res 2011;13(5):R87.

Telmanci K, Levine D, Smith RV, Brandwein-Gensler M, Staffenberg DA, Garg MK, et al.
Metastatic apocrine carcinoma of the scalp: Prolonged response to systemic che-
motherapy. J Clin Oncol 2010;28(24):e4124.

Zelger BG, Steilmueller I, Dunst KM, Zelger B. Solid apocrine carcinoma of the skin: Re-
port of a rare adnexal neoplasm mimicking lobular breast carcinoma. J Cutan Pathol 2008;35(3):332e6.